

ASTRAZENECA: AZN: Omthera Acquisition – Valuations defensive, leaves room for upside

https://marketpublishers.com/r/A3B8C6A34CAEN.html

Date: May 2013

Pages: 3

Price: US\$ 90.00 (Single User License)

ID: A3B8C6A34CAEN

Abstracts

AstraZeneca today announced acquisition of Omthera Pharma for \$260m in cash and \$120m in form of contingent value rights. The acquisition gives AstraZeneca access to fish oil product Epanova, currently in PhIII (NDA filing expected mid 2013) for the treatment of severe hypertriglyceridemia. Epanova clinical profile as a standalone fish oil drug may not be as good as Amarin's Vascepa (Table X), but we believe the fixed dose combination of Crestor and Epanova should be a potent one and comparable to Vascepa (Chart X). In the STELLAR study, Crestor demonstrated that it is more potent than most other statins (except Lipitor) in the reduction of triglycerides.



I would like to order

Product name: ASTRAZENECA: AZN: Omthera Acquisition – Valuations defensive, leaves room for

upside

Product link: https://marketpublishers.com/r/A3B8C6A34CAEN.html

Price: US\$ 90.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

First name:

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/A3B8C6A34CAEN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

